Credit Suisse Downgrades Diplomat Pharmacy (DPLO) to Underperform on Slowing Organic Growth, Profit Challenges

November 23, 2016 6:13 AM EST
Get Alerts DPLO Hot Sheet
Price: $14.29 +0.92%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade DPLO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Credit Suisse downgraded Diplomat Pharmacy (NYSE: DPLO) from Neutral to Underperform with a price target of $13.00 (from $18.00) on continuing growth, profitability concerns.

Analyst Robert Willoughby commented, "We are incrementally negative on DPLO's slowing organic growth and profit challenges that exacerbate our concerns over its limited value proposition to health care payors. DPLO will not grow operating income in 2017, and while acquisitions may compensate for slowing growth, its invested capital base is ballooning. The 3Q16 guidance set removes some near term risk, but our conviction in our EPS estimates is lower, and a clear pathway to higher ROIC is still not apparent."

For an analyst ratings summary and ratings history on Diplomat Pharmacy click here. For more ratings news on Diplomat Pharmacy click here.

Shares of Diplomat Pharmacy closed at $14.46 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, Downgrades, Hot Downgrades

Related Entities

Credit Suisse, Robert Willoughby

Add Your Comment